<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
23.05.2019 07:14:45

Press Release: Novartis highlights company transformation, catalyst-rich pipeline, and strong progress on strategy at Meet Novartis Management investor event

Novartis International AG / Novartis highlights company transformation,

catalyst-rich pipeline, and strong progress on strategy at Meet Novartis

Management investor event. Processed and transmitted by West

Corporation. The issuer is solely responsible for the content of this

(Anzeige)Passende neue Barrier Reverse Convertibles

announcement.

-- Driving growth through cutting edge pipeline with 15 in-market

blockbusters and more than 25 potential blockbusters in development,

including 10+ planned launches by 2021

-- Strong progress on productivity efforts to expand margins with

acceleration of key growth drivers, together with productivity efforts in

Novartis Technical Operations and Business Services

-- Building leadership in advanced therapy platforms with 18 projects in

clinical development

-- Continuing a multi-year journey to build a new culture and create lasting

trust and impact with society

Basel, May 23, 2019 - Novartis hosts its annual Meet Novartis Management

event today at its Research headquarters in Cambridge, Massachusetts,

giving investors and industry analysts the opportunity to meet with key

executives across the company in six separate breakout sessions. The

meeting provides a deeper view into the company's progress on its

ongoing transformation and strategy for sustainable value creation.

"Novartis is on track to become a leading medicines company powered by

advanced therapy platforms and data science, and is on track to deliver

sustained accretive growth. We are developing and launching medicines

that can change the standard of care in devastating diseases. Our

pipeline is industry-leading with more than 25 potential blockbusters

and this pace of innovation positions Novartis well for the future",

said Novartis CEO, Vas Narasimhan.

In the Pharmaceuticals business unit, management highlights the

continued strength of Cosentyx and Entresto and preparation for an

unprecedented wave of launches. Strong momentum continues for key growth

drivers based on a growing evidence base, including the PIONEER data

supporting hospital initiation of Entresto. The team is ready to launch

five blockbuster candidates in core therapeutic areas over the next two

years - Mayzent, Zolgensma[1], Brolucizumab (RTH258), Ofatumumab

(OMB157), and Fevipiprant (QAW039). Novartis also expects double-digit

growth in China, capitalizing on faster and broader access.

Novartis is one of the leading Oncology companies with growth

opportunities in Targeted Therapy, Cell Therapy, Radioligand Therapy and

Immunotherapy. Oncology returned to growth in 2018 and the pipeline and

portfolio are well positioned for future growth. Oncology has a rich

portfolio with seven in-market blockbusters, three recent launches with

blockbuster potential and a strong, unique pipeline across the

platforms. By integrating the best internal and external innovations,

Novartis is positioned to continue to lead in Oncology.

The Global Drug Development (GDD) team provides insight into the

catalyst-rich pipeline that contains more than 25 potential

blockbusters. Novartis has multiple 2019 pipeline milestones, including

six major readouts that have the potential to accelerate Novartis'

growth trajectory. These 2019 readouts include Pharmaceuticals Entresto

(HF-pEF) and Fevipiprant (asthma) and in Oncology the first combination

with the Novartis PD1, spartalizumab (PDR001). GDD is building out

advanced therapy platform capabilities to complement small molecules and

biologics. The team is focused on operational execution with extensive

use of data and digital technologies to reduce trial time and cost and

improve productivity.

Our rich late stage pipeline is fuelled by a steady flow of emerging

assets from the Novartis Institutes for Biomedical Research (NIBR). NIBR

is a leading center of therapeutics discovery research with a proven

record of delivering innovative therapies. Novartis has a deep pipeline

of 90 new molecular entities prioritized and optimized for

transformative potential and resourced for competitive advantage. NIBR

is deploying a suite of advanced technology platforms in an effort to

drug targets that were previously considered "undruggable". A focused

research strategy, accelerating the most promising internal and early

external opportunities, is helping NIBR deliver transformative

innovation and curate a first-in-class portfolio.

In Sandoz, management provides an update on its continuing

transformation and the evolving generics landscape. While the US market

is being impacted by pricing pressure, approximately 70% of Sandoz sales

come from outside the US where sales are growing and driving margin

expansion. Sandoz is shaping its portfolio to drive sustainable and

profitable growth, including the divestment of the US oral solids and

dermatology portfolio planned to complete in 2019. Sandoz is a leader in

Biosimilars with 8 on the market and 10+ in the pipeline. The division

is becoming leaner and more agile to drive sustainable sales and margin

growth in a rapidly-moving generics environment.

In closing, Group management reiterates the overall strategy to become a

leading medicines company powered by advanced therapy platforms and data

science. Novartis is building depth across the core therapeutic areas by

advancing a highly productive and valuable pipeline. There is a clear

path to expand margins through acceleration of key growth drivers,

together with productivity efforts in NTO and NBS. Novartis remains

disciplined and shareholder-focused in its capital allocation, including

maintaining a strong and growing dividend and doing value-creating

bolt-on deals. We are focused on building lasting trust with society, we

are ranked #2 on the access to medicines index and we are committed to

addressing global health challenges including malaria, leprosy and

sickle cell. Our culture is transforming to become inspired, curious and

unbossed. Novartis management is focused on driving its strategy and

sustainable growth.

[1] The brand name Zolgensma(R) has been provisionally approved by the

FDA for the investigational product AVXS-101 (onasemnogene

abeparvovec-xioi), but the product itself has not received marketing

authorization or BLA approval from any regulatory authorities.

For background slides and webcast (audio only) please refer to the

following link:

http://www.novartis.com/investors/event-calendar/index.shtml

The background slide decks will be available on Thursday May 23, 2019 at

7am EST.

Disclaimer

This press release contains forward-looking statements within the

meaning of the United States Private Securities Litigation Reform Act of

1995, that can generally be identified by words such as "pipeline,"

"strategy," "driving," "potential," "development," "planned," "launces,"

"to expand," "continuing," "sustainable," "on track," "to deliver

sustained accretive growth," "developing," "launching," "positions,"

"future," "momentum," "ready to launch," "candidates," "expects,"

"opportunities," "positioned," "to become," "milestones," "focused," "to

reduce," "steady flow," "is deploying," "promising," "evolving,"

"growing," "driving," "shaping," "planned," "advancing," "path,"

"maintaining," "committed," "transforming," or similar expressions, or

by express or implied discussions regarding potential new products,

potential new indications for existing products, or regarding potential

future revenues from any such products; or regarding the potential

outcome, or financial or other impact on Novartis, of the spinoff of our

Alcon Division, or of the proposed divestiture of certain portions of

our Sandoz Division business in the US; or regarding potential future

sales or earnings of the Group or any of its divisions or potential

shareholder returns; or by discussions of strategy, plans, expectations

or intentions. Such forward-looking statements are based on the current

beliefs and expectations of management regarding future events, and are

subject to significant known and unknown risks and uncertainties. Should

one or more of these risks or uncertainties materialize, or should

underlying assumptions prove incorrect, actual results may vary

materially from those set forth in the forward-looking statements. You

should not place undue reliance on these statements. In particular, our

expectations could be affected by, among other things: global trends

toward healthcare cost containment, including ongoing government, payer

and general public pricing and reimbursement pressures and requirements

for increased pricing transparency; regulatory actions or delays or

government regulation generally, including potential regulatory actions

or delays with respect to the development of the products or the

proposed transactions described in this release; the potential that the

strategic benefits, synergies or opportunities expected from the Alcon

and Sandoz transactions may not be realized or may be more difficult or

take longer to realize than expected; the inherent uncertainties

involved in predicting shareholder returns; the uncertainties inherent

in the research and development of new healthcare products, including

clinical trial results and additional analysis of existing clinical

data; our ability to obtain or maintain proprietary intellectual

property protection, including the ultimate extent of the impact on

Novartis of the loss of patent protection and exclusivity on key

products that commenced in prior years and will continue this year;

safety, quality or manufacturing issues; uncertainties regarding actual

or potential legal proceedings, including, among others, actual or

potential product liability litigation, litigation and investigations

regarding sales and marketing practices, intellectual property disputes

and government investigations generally and potential litigation with

respect to the proposed transactions; uncertainties involved in the

development or adoption of potentially transformational technologies and

(MORE TO FOLLOW) Dow Jones Newswires

May 23, 2019 01:15 ET (05:15 GMT)